In the SP263 assay, tumor proportion score (TPS) ≥ 25% is used as the cutoff, and in the 28-8 and 22C3 assays, TPS ≥ 1% is used as the cutoff to predict PD-L1 positivity in NSCLC [9, 15]. This evidence concerns the gene CD274 and neoplasm.